Status:
TERMINATED
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
Lead Sponsor:
University of Calgary
Conditions:
Anterior Cruciate Ligament Tear
Anterior Cruciate Ligament Rupture
Eligibility:
All Genders
25-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess if a zoledronic acid injection can alter the trajectory of joint degeneration following an acute anterior cruciate ligament (ACL) injury.
Detailed Description
After being informed about the study and potential risks and all participants giving written informed consent, this project will establish a cohort of young men and women who within six weeks have sus...
Eligibility Criteria
Inclusion
- Clinical evidence of an acute unilateral ACL tear (full-thickness, complete tear) will be recruited. This age range is chosen to ensure participants have fully developed adult bone structures and to exclude participants with menopause as this could affect study results.
- Participants with combined ligament deficiencies (posterior cruciate, medial and/or lateral collateral) or meniscal injury will be included. Participants must be able to fully extend the knee while supported at the time of the baseline measurement in order to conduct the HR-pQCT scan.
- Participants with a serum calcium level in the normal range (2.10-2.60 mmol/L) and a creatinine level above 59 (reported as eGFR) will be included.
Exclusion
- Individuals with contraindications to zoledronic acid (see below)
- Prior knee ligament and/or meniscus tears, and/or intra-articular fractures.
- Females who are pregnant or planning pregnancy within a year will not be eligible. The research team will recommend participants who are planning to become pregnant within the next five years to withdraw their participation.
- Individuals with knees larger than the CT scanner's circular field of view.
- Individuals with a history of disease and/or treatment affecting bone turnover in the past 12 months.
- Individuals with injuries or implants that are not MRI-safe.
- Zoledronic acid is contraindicated for:
- Patients who are hypersensitive to this drug or to any ingredient in the formulation, or to any bisphosphonates or component of the container.
- Severe renal impairment with creatinine clearance \<35 mL/min and in those with evidence of acute renal impairment. For this study, participants with a creatinine clearance \<50 mL/min may be excluded.
- Non-corrected hypocalcaemia at the time of infusion.
- Pregnant and nursing mothers.
- Patients who are already taking another bisphosphonate (ex. for osteoporosis).
Key Trial Info
Start Date :
May 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2025
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05204836
Start Date
May 16 2023
End Date
July 3 2025
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N 1N4